Passa al contenuto
Merck
Tutte le immagini(7)

Documenti

792500

Sigma-Aldrich

Sodium pyruvate

anhydrous, free-flowing, Redi-Dri™, ReagentPlus®, ≥99%

Sinonimo/i:

α-Ketopropionic acid sodium salt, 2-Oxopropanoic acid sodium salt, Pyruvic acid sodium salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(7)

About This Item

Formula condensata:
CH3COCOONa
Numero CAS:
113-24-6
Peso molecolare:
110.04
Beilstein:
3568341
Numero CE:
204-024-4
Numero MDL:
MFCD00002586
Codice UNSPSC:
12352100
ID PubChem:
329768338

Grado

anhydrous

Livello qualitativo

100

Nome Commerciale

ReagentPlus®
Redi-Dri™

Saggio

≥99%

Forma fisica

powder

Qualità

free-flowing

Perdita

≤0.5% loss on drying

Punto di fusione

>300 °C (lit.)

Solubilità

H2O: 100 mg/mL, clear, colorless to faintly yellow

Cationi in tracce

heavy metals (as Pb): ≤20 ppm

Temperatura di conservazione

2-8°C

Stringa SMILE

[Na+].CC(=O)C([O-])=O

InChI

1S/C3H4O3.Na/c1-2(4)3(5)6;/h1H3,(H,5,6);/q;+1/p-1
DAEPDZWVDSPTHF-UHFFFAOYSA-M

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Note legali

ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
Redi-Dri is a trademark of Sigma-Aldrich Co. LLC

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H317 - H319

Classi di pericolo

Eye Irrit. 2 - Skin Sens. 1B

Codice della classe di stoccaggio

13 - Non Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number
SLBZ3119
SLBV6133
SLBX1167
SLCB7973
SLBP4879V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 3

1 of 3

Pyruvic acid sodium salt for biochemistry

Millipore

1.06619

Pyruvic acid sodium salt

2-Phospho-L-ascorbic acid trisodium salt ≥95.0% (HPLC)

Sigma-Aldrich

49752

2-Phospho-L-ascorbic acid trisodium salt

Acido piruvico natural, ≥95%, FG

Sigma-Aldrich

W297070

Acido piruvico

Rekin's Janky et al.
PLoS computational biology, 10(7), e1003731-e1003731 (2014-07-25)
Identifying master regulators of biological processes and mapping their downstream gene networks are key challenges in systems biology. We developed a computational method, called iRegulon, to reverse-engineer the transcriptional regulatory network underlying a co-expressed gene set using cis-regulatory sequence analysis.
Lotta Tengroth et al.
PloS one, 9(6), e98239-e98239 (2014-06-03)
The human nasal epithelium is an important physical barrier, and a part of the innate immune defense that protect against pathogens. The epithelial cells recognize microbial components by pattern-recognition receptors (PRRs), and thereby trigger an immune response. Even though TLR3
Tetsufumi Ito et al.
The Journal of comparative neurology, 523(15), 2277-2296 (2015-04-17)
Large GABAergic (LG) neurons form a distinct cell type in the inferior colliculus (IC), identified by the presence of dense VGLUT2-containing axosomatic terminals. Although some of the axosomatic terminals originate from local and commissural IC neurons, it has been unclear
Yoh Arita et al.
Nature communications, 5, 4552-4552 (2014-07-30)
The origin and developmental mechanisms underlying coronary vessels are not fully elucidated. Here we show that myocardium-derived angiopoietin-1 (Ang1) is essential for coronary vein formation in the developing heart. Cardiomyocyte-specific Ang1 deletion results in defective formation of the subepicardial coronary
Philipp Müller et al.
Science translational medicine, 7(315), 315ra188-315ra188 (2015-11-27)
Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy. We show that T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer (WSG-ADAPT
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.